

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>AK Holding Company, LC</u> (Last) (First) (Middle) <u>3200 WEST CLUBHOUSE DRIVE</u> <u>SUITE 200</u> (Street) <u>LEHI UT 84043</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>12/03/2020</u>	3. Issuer Name and Ticker or Trading Symbol <u>Clene Inc. [CLNN]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock⁽¹⁾</u>	<u>5,135,676</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Senior Warrant to Purchase Common Stock⁽²⁾</u>	<u>12/30/2020</u>	<u>04/08/2023</u>	<u>Common Stock</u>	<u>160,121</u>	<u>1.97</u>	<u>D</u>	
<u>Series A Warrant to Purchase Common Stock⁽³⁾</u>	<u>12/30/2020</u>	<u>04/04/2023</u>	<u>Common Stock</u>	<u>864,121</u>	<u>1.97</u>	<u>D</u>	

Explanation of Responses:

- The securities owned by AK Holding Company, LC (including the Warrant and Senior Warrant described below) may also be deemed to be owned by Alan Ashton and Karen Ashton. Mr. and Mrs. Ashton each own 50% of the membership interests in AK Holding Company, LC.
- Senior Warrant ("Senior Warrant") to purchase Series D Preferred Stock, issued by Clene Nano-Medicine Inc. to AK Holding Company, LC dated April 8, 2013 and currently exercisable for shares of Clene Inc. The Senior Warrant owned by AK Holding Company, LC may also be deemed to be owned by Alan Ashton and Karen Ashton. Mr. and Mrs. Ashton each own 50% of the membership interests in AK Holding Company, LC.
- Warrant ("Warrant") to purchase Series A Preferred Stock, such warrant issued by Clene Nanomedicine, Inc. to AK Holding Company, LC on April 4, 2013 and currently exercisable for Clene Inc. common stock. The Warrant may also be deemed to be owned by Alan Ashton and Karen Ashton. Mr. and Mrs. Ashton each own 50% of the membership interests in AK Holding Company, LC.

David Harkness

01/06/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.